Winan van Houdt, Surgical Oncologist at Antoni van Leeuwenhoek/the Netherlands Cancer Institute, shared on LinkedIn:
“A privilege it was to be invited to the Spanish ‘chirurgendagen’ to discuss the rationale behind neoadjuvant strategies for soft tissue sarcomas.
Updating our Spanish collaborators on the EORTC – European Organisation for Research and Treatment of Cancer STRASS2 and STREXIT trial (neo-adjuvant chemo for high risk retroperitoneal sarcomas), already 8 Spanish patients have been randomised and hopefully more to follow!
Wonderful hosts and so good to share knowledge and strengthen collaborations.
Thanks to Lorena Cambeiro, Jose Gonzalez, Hugo Vasquez, Pablo Lozano Lominchar.”
Other articles about soft tissue sarcomas on OncoDaily.